Lowenstein Sandler advised Sonnet BioTherapeutics, while Sullivan & Worcester advised Chardan Capital Markets on the offering. Sonnet BioTherapeutics Holdings, Inc. (Nasdaq: SONN), a clinical-stage company developing...
You must be a Standard 1 Year member to access this content.
Locke Lord advised Professional Diversity Network, while Sullivan & Worcester represented A.G.P./Alliance Global Partners in the offering. Professional Diversity Network, Inc. (NASDAQ: IPDN) has entered into...
You must be a Standard 1 Year member to access this content.
Dorsey & Whitney advised Shuttle Pharmaceuticals, while Sullivan & Worcester advised A.G.P./Alliance Global Partners in the offering. Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) announced the pricing...
You must be a Standard 1 Year member to access this content.
Jones Day represented Cibus, while Sullivan & Worcester represented ROTH Capital Partners and A.G.P./Alliance Global Partners on the offering. Cibus, Inc. (Nasdaq: CBUS) announced the public...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised BioCardia, while Sullivan & Worcester advised A.G.P./Alliance Global Partners on the offering. BioCardia, Inc. (Nasdaq: BCDA) completed its $7.2 million...
You must be a Standard 1 Year member to access this content.
Patterson Belknap Webb & Tyler and Stearns Weaver Miller Weissler Alhadeff & Sitterson represented Ethicon in the case. Johnson & Johnson’s (J&J) subsidiary Ethicon has obtained...
You must be a Standard 1 Year member to access this content.
